ICD-10 Code F15.20: Other Stimulant Dependence, Uncomplicated

Key Takeaways

F15.20 is a billable ICD-10-CM code for other stimulant dependence, uncomplicated, valid for reimbursement from 2016 through 2026.

Amphetamine, methamphetamine, MDMA, and caffeine fall under F15.20; cocaine is explicitly excluded and coded under F14 instead.

F15.20 maps to DSM-5 moderate and severe amphetamine-type substance use disorder (4+ criteria); F15.10 covers abuse while F15.90 covers unspecified stimulant use.

Pabau’s claims management software and mental health EMR support accurate stimulant use disorder coding workflows for behavioral health practices.

Stimulant use disorder claims are among the most frequently miscoded diagnoses in behavioral health billing. Coders routinely confuse dependence with abuse, misroute cocaine-related encounters to the F15 category, or select the non-specific parent code F15.2 rather than the billable child code F15.20. Each of these errors creates claim rejections, audit exposure, and delayed reimbursement for mental health practices and addiction treatment programs. This guide covers the definition, applicable stimulants, DSM-5 alignment, related codes, and documentation requirements for ICD-10 Code F15.20.

According to the Centers for Medicare and Medicaid Services (CMS), ICD-10-CM codes in the F10-F19 range classify mental and behavioral disorders due to psychoactive substance use. Within that range, the F15 subcategory specifically governs other stimulant-related disorders, making precise code selection essential for clinicians, coders, and billing teams handling stimulant use disorder encounters.

ICD-10 Code F15.20: Definition and Clinical Description

ICD-10 Code F15.20 represents “Other stimulant dependence, uncomplicated.” It is a billable and specific ICD-10-CM code, meaning it is valid for use on claims submitted for reimbursement purposes. The code has been active continuously from 2016 through the 2026 code year without modification to its clinical description.

“Uncomplicated” in this context means the dependence is present but not accompanied by intoxication, withdrawal, mood disorder, psychosis, sleep disorder, sexual dysfunction, or delirium. Those comorbid presentations have their own child codes within the F15.2 subcategory, such as F15.221 for dependence with intoxication delirium or F15.23 for dependence with withdrawal. When none of those complications are documented, F15.20 is the correct selection.

The code sits within the following classification hierarchy according to the CDC/NCHS ICD-10-CM tabular list:

• Chapter: F01-F99 (Mental, Behavioral and Neurodevelopmental Disorders)
• Block: F10-F19 (Mental and behavioral disorders due to psychoactive substance use)
• Category: F15 (Other stimulant related disorders)
• Subcategory: F15.2 (Other stimulant dependence)
• Code: F15.20 (Other stimulant dependence, uncomplicated)

F15.2 is the non-billable parent code. Never submit F15.2 on a claim. Only F15.20 and its sibling codes (F15.21, F15.221, F15.23, etc.) carry the billable/specific designation that payers require. Submitting the parent code results in a claim edit or rejection at the clearinghouse level for psychiatry and addiction medicine practices.

Stimulants Covered Under F15.20

The ICD-10-CM “Applicable To” note for F15.20 identifies the substance class covered. Coders frequently ask which stimulants belong here versus in other code categories.

The Excludes1 note at the F15 category level is a hard exclusion, not a guidance note. It means cocaine-related disorders cannot be coded with F15 codes simultaneously. A patient presenting with both cocaine and amphetamine dependence requires separate codes: F14.20 for the cocaine component and F15.20 for the amphetamine component. Attempting to capture both under a single F15.20 code misrepresents the clinical encounter and violates ICD-10-CM Official Guidelines for Coding and Reporting maintained by the National Center for Health Statistics (NCHS) and CMS.

DSM-5 Alignment for F15.20

ICD-10-CM “Applicable To” notes provide DSM-5 crosswalk guidance. For F15.20, the Applicable To notes list four terms: “Amphetamine type substance use disorder, moderate,” “Amphetamine type substance use disorder, severe,” “Other or unspecified stimulant use disorder, moderate,” and “Other or unspecified stimulant use disorder, severe.” This confirms that F15.20 maps to both moderate (4 to 5 criteria) and severe (6 or more criteria) amphetamine-type substance use disorder under DSM-5, as well as other/unspecified stimulant use disorders at both severity levels.

For severe disorder (6 or more criteria), the correct ICD-10-CM code remains F15.20 when uncomplicated. The DSM-5 severity specifier of “severe” does not automatically trigger a different ICD-10-CM code unless complications (such as withdrawal or psychosis) are also documented and coded. Clinicians documenting stimulant use disorder for psychology and addiction counseling practices should include the DSM-5 criteria count in the clinical note to support the code assignment.

Differentiating F15.20 from Related Codes

The F15 category contains codes spanning use, abuse, and dependence. Selecting the correct severity level is the most common source of coding errors in stimulant use disorder claims.

F15.10 vs. F15.20: The critical distinction is the severity of the use disorder diagnosis. F15.10 applies when DSM-5 criteria are met at the mild threshold (2 to 3 criteria). F15.20 applies at the moderate and severe thresholds (4 or more criteria). The ICD-10-CM Official Guidelines include an Excludes1 relationship between the two codes, meaning they cannot be reported together for the same substance on the same claim. A coder who assigns both F15.10 and F15.20 for one encounter will generate a coding edit.

F15.20 vs. F15.90: F15.90 represents stimulant use, unspecified. Use it only when the clinical documentation does not specify whether the pattern meets the threshold for abuse or dependence. It is a default code, not a first choice. Payers increasingly scrutinize unspecified codes during audits, so adequate documentation in structured clinical intake forms should support a more specific assignment whenever possible.

F15.21 (in remission): When a patient with previously documented stimulant dependence is now abstinent and meets DSM-5 remission criteria, F15.21 replaces F15.20. The clinical note must explicitly document the remission status and ideally reference the duration (early vs. sustained remission per DSM-5). For comparison, ICD-10-CM handles other behavioral and mood disorder remission patterns similarly; see the Pabau guide to situational anxiety ICD-10 coding for related documentation considerations.

ICD-10 Code F15.20 Documentation Requirements

Accurate documentation is what separates a defensible claim from a denial or clawback. For ICD-10 Code F15.20, the clinical record must support three distinct elements.

• Substance identification: The note must name the specific stimulant involved (amphetamine, methamphetamine, MDMA, etc.). “Stimulant dependence” without substance specification weakens the claim and may prompt a query from the coder.
• Severity specification: The documentation must reflect DSM-5 criterion count or explicitly state “moderate” or “severe” to distinguish F15.20 from F15.10 (mild) or F15.90 (unspecified).
• Absence of complications: To justify the “uncomplicated” specifier, the note must either confirm no current intoxication or withdrawal is present or document that the encounter was not primarily focused on a complication. If intoxication delirium, withdrawal, or psychosis is documented, a more specific child code within F15.2x applies instead.

Practices using compliance-focused clinical documentation tools can build structured note templates that prompt clinicians to capture all three elements at every substance use disorder encounter. This reduces coding queries and supports first-pass claim acceptance.

For ADHD and dual-diagnosis practices that frequently manage stimulant use alongside stimulant treatment (e.g., patients prescribed amphetamine-based ADHD medications who develop dependence), the documentation must clearly distinguish between therapeutic use and a diagnosed use disorder. The clinical note should address whether the F15.20 diagnosis applies to prescribed stimulants, illicit stimulants, or both, as this distinction affects both the clinical care plan and the coding accuracy.

ICD-10-CM Hierarchy and Related Code Crosswalks

Coders and billing teams working across multiple systems or legacy platforms need accurate crosswalk data when converting or verifying F15.20 records.

ICD-9-CM crosswalk: F15.20 converts approximately to ICD-9-CM 304.40 (Amphetamine and other psychostimulant dependence, unspecified). This is an approximate crosswalk, not an exact match. Some conversion tools also map F15.20 to 304.41 (continuous) depending on documentation specificity. Use the AAPC Codify ICD-10-CM lookup to verify crosswalk accuracy for individual encounters.

MS-DRG assignment: For inpatient encounters where F15.20 is listed, the code participates in MS-DRG grouping logic for substance use and substance-induced mental disorder DRGs. The specific DRG assigned depends on the principal diagnosis, comorbidities, and presence of major complication or comorbidity (MCC) or complication or comorbidity (CC) designations. Behavioral health coders handling inpatient substance use admissions should verify current MS-DRG tables through the CMS ICD-10-CM resources page.

CPT codes commonly paired with F15.20: Substance use disorder treatment encounters coded with F15.20 as the diagnosis typically pair with CPT codes for individual psychotherapy (90832, 90834, 90837), group therapy (90853), or substance use disorder evaluation and management visits. When medication-assisted treatment (MAT) is involved, HCPCS codes for the relevant drug (e.g., buprenorphine products) may also accompany the claim. The claims management workflow must map diagnosis codes to procedure codes correctly to avoid medical necessity denials.

Streamline Substance Use Disorder Coding in Your Practice

Pabau's mental health EMR and claims management tools help behavioral health practices document stimulant use disorder accurately, reduce coding errors, and support first-pass claim acceptance.

Book a demo

Comorbid Coding Scenarios

Stimulant use disorder rarely presents in isolation. Understanding how to sequence F15.20 with comorbid diagnoses prevents sequencing errors that trigger claim edits or denials.

Stimulant-induced mood disorder: When amphetamine dependence produces a mood disorder that would not exist independently of the substance use, the correct coding approach is to sequence the substance use disorder code (F15.20) first, followed by the stimulant-induced mood disorder code from the F15.24 range. Do not assign an independent depressive or bipolar disorder code (F32, F33, F31) if the mood symptoms are substance-induced and not a separate diagnosis. For reference, the Pabau clinical guide on ICD-10 coding for comorbid mental health conditions covers similar sequencing principles for behavioral diagnoses.

Dual diagnosis (independent mood disorder with stimulant dependence): When the clinical record supports that a mood disorder exists independently of the stimulant use (i.e., the disorder preceded the substance use or persists during sustained abstinence), both diagnoses may be coded. In this scenario, sequencing depends on which condition drove the encounter. If the primary reason for the visit was the mood disorder, the mood disorder code leads; F15.20 is listed as an additional diagnosis.

Stimulant dependence with ADHD: Patients with ADHD who develop stimulant dependence present a dual-coding scenario. The ICD-10-CM Official Guidelines do not prohibit coding both conditions simultaneously. However, the clinical documentation must clearly differentiate between therapeutic stimulant use for ADHD management and the dependence pattern. Practices managing this population benefit from structured documentation within their ADHD-focused clinic software.

Billing and Reimbursement Context

F15.20 is a reimbursement-eligible diagnosis code for commercial payers, Medicare, and Medicaid, though coverage terms vary by payer and plan. Several practical billing considerations apply.

Prior authorization: Intensive outpatient programs (IOP) and residential treatment facilities treating stimulant dependence commonly require prior authorization with F15.20 as the supporting diagnosis. The authorization request should include the DSM-5 severity documentation and treatment plan to reduce back-and-forth with the payer’s utilization management team. Using a digital forms workflow to capture structured clinical data at intake strengthens authorization submissions.

HIPAA code set compliance: Under HIPAA’s Administrative Simplification provisions, ICD-10-CM is the required diagnostic code set for all HIPAA-covered transactions. Submitting F15.20 on a CMS-1500 or 837P electronic claim satisfies this requirement. Practices must ensure their practice management or billing software maps the current-year ICD-10-CM code descriptions, as outdated software may use prior-year code files that no longer match the active code set. The WHO ICD-10 browser provides the international classification reference for F15.20’s parent structure.

Claim edit exposure: Commercial payers use claims editing software that flags diagnosis-procedure code combinations for medical necessity review. F15.20 paired with low-acuity E/M codes (99211, 99202) may trigger edits if the clinical documentation does not reflect the level of decision-making typical for a substance use disorder management visit. Practices using integrated claims management software can identify these mismatches before submission rather than after denial.

Expert Picks

Need structured documentation tools for substance use disorder visits? Mental Health EMR covers how Pabau supports behavioral health documentation workflows, including structured note templates for substance use disorder coding.

Looking for a psychiatric evaluation framework? Psychiatric Evaluation Template provides a step-by-step guide for comprehensive mental health and substance use disorder assessments.

Want to reduce claim denials in your behavioral health practice? Claims Management Software explains how Pabau’s billing tools support accurate diagnosis-procedure code pairing and first-pass claim acceptance.

Conclusion

Miscoding stimulant use disorder is one of the more preventable sources of claim denials and audit risk in behavioral health billing. The distinction between F15.10, F15.20, and F15.90 hinges entirely on what the clinical documentation supports, which means the coding problem is actually a documentation problem.

Pabau’s mental health EMR includes structured intake forms and clinical note templates designed to capture DSM-5 severity criteria, substance identification, and complication status at every encounter, giving coders the information they need to assign F15.20 accurately. To see how Pabau handles substance use disorder documentation and claims workflows, book a demo.

Frequently Asked Questions